Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
525
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-Dependent Prevalence of Sagittal Skeletal, Dental Malocclusions in Romanian Orthodontic Patients: An Observational Study.

Journal of clinical medicine·2026
Same author

Traditional and Modern Predictors of Atherosclerotic Cardiovascular Disease in Patients with T2D and MASLD.

Diagnostics (Basel, Switzerland)·2026
Same author

Lipid Signatures Associated with Diabetic Peripheral Neuropathy in Obesity and Type 2 Diabetes-A Systematic Review.

Journal of clinical medicine·2026
Same author

MASLD and Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Systematic Review.

Medicina (Kaunas, Lithuania)·2026
Same author

Vitamin D and Vitamin B<sub>12</sub> in Psychiatric Disorders: An Exploratory Systematic Review and Meta-Analysis of Nutrient-Specific Status and Supplementation Evidence.

Diseases (Basel, Switzerland)·2026
Same author

Clinical and Inflammatory Determinants of Heart Failure Severity Following Myocardial Infarction: Implications for Post-Infarction Care.

Journal of cardiovascular development and disease·2026

Related Experiment Video

Updated: Jan 16, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

5.7K

Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.

Mihaela Simona Popoviciu1,2, Delia Reurean-Pintilei3, Teodor Salmen4,5

  • 1Department of Diabetes, Nutrition and Metabolic Diseases-Clinical Section Internal Medicine I, Bihor County Emergency Clinical Hospital, 410169 Oradea, Romania.

Biomedicines
|September 27, 2025
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively manage type 2 diabetes mellitus (T2DM) and obesity. Injectable semaglutide and dulaglutide showed significant improvements in glycemic control and weight reduction in Romanian patients over six months.

Keywords:
GLP-1 receptor agonistsType 2 diabetes mellitusdulaglutideexenatideglycemic controlobesityreal-world evidencesemaglutide

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

906
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.6K

Related Experiment Videos

Last Updated: Jan 16, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

5.7K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

906
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.6K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity and type 2 diabetes mellitus (T2DM) are rising globally, increasing cardiometabolic risk.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended for T2DM patients with excess weight and cardiovascular risk.

Purpose of the Study:

  • To evaluate the real-world effectiveness of GLP-1 RAs in Romania.
  • To assess glycemic control, body weight reduction (BWR), and waist circumference (WC) changes in T2DM patients with excess weight.

Main Methods:

  • Prospective observational study involving 311 adult T2DM patients (HbA1c > 7.2%, BMI ≥ 25 kg/m²).
  • Patients received exenatide, oral or injectable semaglutide, or dulaglutide for 6 months.
  • Key parameters monitored: HbA1c, body weight, BMI, and WC.

Main Results:

  • All GLP-1 RAs significantly improved HbA1c, BMI, and WC (p < 0.05).
  • Dulaglutide showed the greatest HbA1c reduction (-6.69 ± 0.91%).
  • Injectable semaglutide achieved the most significant BWR (-4.60 ± 2.74 kg) and WC reduction, particularly in males.

Conclusions:

  • GLP-1 RAs offer substantial metabolic benefits in real-world T2DM management.
  • These agents should be integral to personalized treatment plans for overweight/obese T2DM patients.